overview of non-clinical assessment in drug development (8/14) redi 2017
Published 4 years ago • 15K plays • Length 54:28Download video MP4
Download video MP3
Similar videos
-
31:21
benefit-risk considerations in drug development (6/14) redi 2017
-
44:31
nonclinical safety assessment for small molecules and biologic drug development (6of14) redi 2018
-
46:00
introduction to investigational new drug (ind) applications (3/14) redi 2017
-
3:54
the four phases of clinical trials | diversity in clinical trials | akf
-
17:17
fda meetings drug development process | regulatory affairs |
-
15:00
filing review – do’s and don’ts (14/28) generic drugs forum 2017
-
5:47
how biomarkers can improve the drug development process
-
1:02:19
chemistry and manufacturing requirements for early clinical development: what’s in there? prove it.
-
4:33
the drug development process
-
40:24
fda communication during drug development (4/14) redi 2017
-
21:11
developing and implementing science-based standards in bioequivalence assessment
-
42:25
drug development & clinical trials process
-
11:49
janet woodcock, fda, on future innovation in drug development
-
40:26
benefit-risk considerations during drug product development (8of14) redi 2018
-
20:06
major issues and facilities in drug master files (9/15) global quality
-
26:41
small molecule case studies (8of33) quality – oct. 16-17, 2019
-
2:34:13
public webinar: patient-focused drug development draft guidance 3
-
21:20
investigator responsibilities - safety reporting for investigational drugs and devices
-
9:53
complex innovative trial designs pilot meeting program: the process